Slides
Page 1
1 ATOMO DIAGNOSTICS 1Q 2027 RESULTS OVERVIEW 29 OCTOBER 2026
Page 2
2 This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on information available as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment of Atomo as part of its own investigations. This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral communications transmitted or otherwise made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information. The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only. This presentation may contain certain forward-looking statements that are based on Atomo’s beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation). ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) DISCLAIMER ASX: AT1
Page 3
3ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) ATOMO DIAGNOSTICS – 1Q27 Quarterly Highlights ASX: AT1 Transitioning to sustainable revenue growth with an expanding new product pipeline PIPELINE MILESTONES COMMERCIAL PERFORMANCE Upfront Diagnostics + Atomo partnership Next-generation rapid Pre-Hospital LVTWO Brain Disease Test. Generation 4 HIV development agreement With Innovation Scientific PTY LTD, adding to Atomo’s proprietary product development pipeline. Active Syphilis transfers to manufacturing Preparation progresses for clinical trials to begin in the new calendar year. $1.63m TOTAL Q1 2027 REVENUE 140% quarter-on-quarter $939k FEBRIDX®/OEM REVENUE 469% quarter-on-quarter $2.51m CASH RECEIPTS $2.40m from customer receipts + $84k CRC-P Active Syphilis grant; $2.67m quarter-end cash
Page 4
Q1 PERFORMANCE HIV SALES GROWTH | YOY +38.3% Q1 FY27 versus Q1 FY26 HIV SALES Q1 FY26 $456k Q1 FY27 $630k WHERE Q1 SALES CAME FROM INTERNATIONAL | VIATRIS Increased HIV test supply to Viatris Healthcare (Pty) Ltd through the existing international partner relationship. +39.5% ANZ PHARMACY SALES QOQ Australian wholesalers +41.3% New Zealand retail +30.3% ADDITIONAL HEALTH & COMMUNITY SUPPLY Existing ANZ health and community accounts placed further orders. Overall HIV Growth International and ANZ pharmacy channels outperformed to deliver 38.3% year-on-year HIV sales growth. ASX: AT1 Global sales growth in HIV franchise led by International supply and ANZ pharmacy channels HIV Q1 REVENUE PERFORMANCE ASX: AT1 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 4
Page 5
ATOMO OEM PERFORMANCE | Q1 Q-ON-Q +469% OEM SALES REVENUE A$165k → A$939k +713% GROWTH IN DEVICES SUPPLIED US FEBRIDX® ADOPTION | LUMOS-REPORTED 215 LIVE US SITES September 2026 +26.5% 170 in July → 215 in September 405 sites under evaluation (350 in July) March 2026 FDA CLIA waiver expanded eligible US testing settings. OEM momentum Flu-season inventory build fuels triple-digit revenue and device-volume growth. Strong QOQ growth driven by Lumos Diagnostics’ FebriDx PASCAL OEM Q1 REVENUE PERFORMANCE ASX: AT1 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 5
Page 6
ASX: AT1 Global licence, development and supply agreement with Innovation Scientific GEN 4 HIV PARTNERSHIP OPENS A NEW COMMERCIAL PATH ASX: AT1 THE MOU AGREEMENT Atomo to receive a global licence to commercialise a rapid Gen 4 HIV assay in its Galileo cassette. Feasibility testing complete. The partnership now moves into final analytical/clinical studiesand regulatory preparation. Parties to negotiate final Supply Agreement and Licence over next four months. WHO DOES WHAT INNOVATION SCIENTIFIC — Complete final assay development — Run analytical and clinical studies with Atomo — Integrate Galileo sub-assemblies with the strip and buffer for finished supply ATOMO — Hold the global assay licence and act as legal manufacturer — Lead IVDR and TGA registration, launch and commercialisation COMMERCIAL PATH 18 MONTHS Planned IVDR and TGA registration window 24 MONTHS Target timing for commercial launch A$1.16bn HIV global rapid-test kit market STRATEGIC FIT Extends Atomo’s Gen 3 HIV + Active Syphilis portfolio; own-pipeline revenue is targeted from late FY2028. Manufacture and supply Galileo sub-assemblies— Source: Future Market Insights, 2026; Market Glass, Inc., 2026; MarketsandMarkets, 2025 6ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 7
GEN 3 | ESTABLISHED - SELF-TEST GEN 4 | NEW PRODUCT - PROFESSIONAL TEST FORMAT Antibody-based HIV self-test OPERATOR Individual self-tester CHANNELS Pharmacy, community, public health, rapid screening POSITION Existing self-testing routes and programs FORMAT Proposed rapid antigen/antibody test OPERATOR Clinicians and trained professionals CHANNELS Sexual health, primary care, clinical POC FOCUS MARKETS Europe/UK, ANZ, APAC, USA INDICATIVE GLOBAL MARKET CONTEXT | DISTINCT 2025 CATEGORY ESTIMATES A$4.62bn All HIV diagnostics A$1.16bn HIV rapid-test kits A$341m HIV self-testing Source: Future Market Insights, 2026; Market Glass, Inc., 2026; MarketsandMarkets, 2025 WHAT GEN 4 BRINGS Expands professional-use buyers, clinical uses and procurement pathways beyond self-testing; overlap remains possible in assisted testing. Potential as market evolves to support ongoing Pre-Exposure Prophylaxis (PrEP) treatment. PrEP is a prescription medicine taken by HIV- negative people to lower the risk of getting HIV. ASX: AT1 Large and growing market opportunity for Atomo’s expanding HIV franchise HIV RAPID TESTING MARKET: GEN 4 and GEN 3 ASX: AT1 MARKETS Europe, UK, ANZ, LMIC, Others ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 7
Page 8
ASX: AT1 Upfront’s biomarker assay moves into Atomo’s technology platform UPFRONT + ATOMO PARTNER ON NEXT -GENERATION TEST ASX: AT1 LVTwo A rapid blood-based brain-disease test designed for use before hospital arrival— helping emergency teams triage suspected stroke or other brain disease patients sooner. PARTNERSHIP ANNOUNCEMENT Atomo and Upfront announce partnership forUpfront’s next-generation test in Atomo’s device. DETECT Proprietary biomarker targets proteins associated with brain disease. DEPLOY Atomo hand-held devices combine blood collection, sample transfer and buffer delivery. DECIDE EARLIER Designed for pre-hospital use to support faster routing and treatment decisions. 9,000 Atomo sub-assemblies supplied for validation and verification activities to date 8ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 9
Sources: Feigin et al. (2025); Stroke Foundation (2024); Stroke Aotearoa NZ; Christensen et al. (2026); CDC (2024). Regional data use different years and methodologies and do not represent addressable test demand. ASX: AT1BRAIN DISEASE BURDEN CREATES A SCALABLE TRIAGE OPPORTUNITY ASX: AT1 GLOBAL CLINICAL NEED 11.9 million new strokes worldwide annually A large, time-critical patient population creates demand for tools that can support earlier stroke triage and routing decisions before hospital arrival. REGIONAL MARKETS 54,800 AUSTRALIA + NEW ZEALAND estimated stroke events per year Australia 45,785 + NZ 9,000 1.46m EUROPE reported stroke events 47 reporting areas · 2023 795,000+ UNITED STATES estimated strokes each year ≈610k first · ≈185k recurrent Pre-hospital stroke triage D-dimer + GFAP assay validation OEM supply as adoption scales PATHWAY FROM CLINICAL NEED TO REGULATORY APPROVAL AND GLOBAL SALES SUSPECTED BRAIN DISEASE TRIAGE INDICATION Ambulance / emergency department VALIDATED RAPID ASSAY Evidence, approval and clinical adoption GLOBAL REGULATORY APPROVALS Gateway to commercial sales → → The partnership will provide a new revenue stream for a significant and exciting new clinical indications ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 9
Page 10
ACTIVE SYPHILIS TRANSFERS TO MANUFACTURING ASX: AT1 Program remains on schedule, with regulator engagement beginning and launch targeted within 18–24 months 10ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) TEST DIFFERENTIATION 15 MINUTES Rapid lateral flow test for home- based and healthcare-practitioner- guided self-testing. ADDRESSES A KEY TESTING GAP Designed to detect infectious syphilis and distinguish active cases from previously treated cases. EARLY CLINICAL PERFORMANCE 100% SENSITIVITY against active syphilis samples by clinical history 99% SPECIFICITY against never-infected patients 93% SPECIFICITY against previously treated cases with clinical history Early clinical testing; results reported by clinical history. PROGRAM ON SCHEDULE TRANSFER COMPLETE Test-strip manufacturing moved from Burnet Institute in Melbourne to Cape Town for clinical- trial production builds. NEXT: CLINICAL TRIALS Trials expected to commence early next year. REGULATORY + LAUNCH Engagement planned with TGA, FDA and BSI; commercial launch targeted within 18–24 months.
Page 11
ASX: AT1 Commercial products fund a broader portfolio progressing through validation, development and feasibility ATOMO PROPRIETARY PRODUCT PIPELINE ASX: AT1 Proprietary portfolio spans established revenue products and new tests targeting decentralised professional and self-test markets. PRODUCT / APPLICATION FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL HIV GEN 3 HIV screening / self-test COMMERCIAL HIV GEN 4 Antibody + p24 antigen DEVELOPMENT ACTIVE SYPHILIS Active vs treated infection VALIDATION LIVER / ALT Liver health screening DEVELOPMENT HCV Hepatitis C virus FEASIBILITY HBV Hepatitis B virus FEASIBILITY ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 11
Page 12
ASX: AT1 Atomo technology enables partner assays to move from technical validation into commercial supply at scale OEM PARTNER PIPELINE ASX: AT1 OEM pipeline focused on professional point-of-care markets and scalable partner supply. PRODUCT / APPLICATION FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL FEBRIDX® Lumos · acute respiratory infection COMMERCIAL FERRITIN Chromacare · iron deficiency VALIDATION BRAIN DISEASE Upfront · pre-hospital triage VALIDATION Atomo technology platforms support multiple partner assays—creating recurring device-supply opportunities as programs progress. PREGNANCY NG Biotech · early pregnancy detection COMMERCIAL 12ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Page 13
1Q27 – PROFIT & LOSS ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) Revenue and gross profit increased strongly year-on-year * Amounts in A$'000; YoY compares Q1 FY27 (unaudited) with Q1 FY26 A$'000 1Q FY27 1Q FY26 YoY change Revenue 1,628 680 +140% Cost of sales (1,204) (424) +184% cost Gross profit 424 256 +66% Gross margin 26% 38% -11.6 pts Other income 217 68 +221% Operating expenditure (1,979) (1,307) +51% cost EBITDA (1,337) (983) +36% loss PBT (1,627) (1,368) +19% loss REVENUE $1.63m 1Q FY26 $0.68m +140% YoY GROSS PROFIT $0.42m 1Q FY26 $0.26m +66% YoY GROSS MARGIN 26% 1Q FY26 38% -11.6 pts YoY EBITDA ($1.34m) 1Q FY26 ($0.98m) +36% loss YoY 13
Page 14
14 1Q27 – BALANCE SHEET ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 1Q FY27 closes with $2.67m in cash, $9.63m in assets and no bank debt * Amounts in A$'000; September 2026 (unaudited) actuals A$'000 1Q FY27 Cash and cash equivalents 2,669 Trade and other receivables 1,301 Inventories 1,723 R&D tax rebate receivable 1,075 Prepayments 327 Total current assets 7,140 Property, plant and equipment 295 Right-of-use assets 297 Intangible assets 823 Development costs 1,070 Total non-current assets 2,485 Total assets 9,625 Total liabilities 3,479 Net assets 6,145 Total equity 6,145 CASH $2.67m available liquidity TOTAL ASSETS $9.63m as at September 2026 NO DEBT $0 bank borrowings
Page 15
1Q27 – CASH FLOW ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) Q1 FY27 ended with $2.67m in cash after a $1.01m net cash outflow * Amounts in A$'000; September 2026 YTD (unaudited) actuals A$'000 Q1 FY27 Receipts from customers 2,401 Payments to suppliers and employees (3,437) Interest received 23 Grant funds received from CRC-P 84 Net cash used in operating activities (929) Property, plant and equipment purchases (17) Net cash used in investing activities (17) Finance lease repayments (69) Net cash used in financing activities (69) Net decrease in cash (1,014) Cash at beginning of period 3,709 Exchange losses (25) Cash at end of period 2,669 CASH AT END $2.67m September 2026 CUSTOMER RECEIPTS $2.40m 1Q FY27 YTD 15
Page 16
16ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) BUILDING A STRONGER BASE FOR SCALABLE GROWTH Commercial momentum is funding a broader product pipeline and a more diversified revenue base $1.63m HIV franchise +38.3% QoQ OEM revenue $938k, up 469% QoQ HIV FRANCHISE LEADS COMMERCIAL TRACTION HIV sales increased 38.3% year on year, led by international supply and ANZ pharmacy channels. FEBRIDX® SHOWS THE POWER OF THE OEM MODEL FebriDx® revenue reached $683k, up 314% year on year, while device supply increased 501%. DIVERSIFICATION BUILDS OVER TIME HIV, pregnancy, and FebriDx® provide the commercial base as the proprietary pipeline and OEM programs in syphilis, Gen 4 HIV, stroke, ferritin, and earlier-stage assays advance. A stronger HIV franchise and scalable OEM model support a broader, more diversified growth platform over time. 1Q REVENUE | +140% QoQ
Page 17
: AT1 For further information, please contact: Cheri Walker, Interim CEO and Executive Director Cheri.Walker@atomodiagnostics.com p. +61 2 9099 4750 Investor Queries Investorqueries@atomodiagnostics.com Atomo Q1 FY27 Quarterly Investor Webinar Presentation Atomo Diagnostics Limited will hold its Q1 FY27 Quarterly Investor Webinar on Tuesday 03rd November 2026 at 2pm (AEDT). To access the webinar, please pre-register by clicking this link To access Atomo’s Investor Hub, please scan the QR code or visit https://investors.atomodiagnostics.com/auth/signup ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 17